Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Availability may be subject to local formulary decisions and current supply constraints
Sarepta has recently confirmed their scale-up plans for calendar 2024, firming up orders and we expect revenue from these top customers to grow approximately 65% this fiscal year as we manufacture product for the US market and the rest of the world to Sarepta and its partners. However, Catalent says it will not be reliant solely on Sarepta in the burgeoning gene therapy space, as numerous projects are moving through the clinic
Tissue Antigens 63 , 562567 (2004)
Similar content being viewed by others Background Many patients with type 2 diabetes (T2D) eventually need a greater potency of injectable glucose-lowering agents (GLAs) because T2D is a progressive disease [1, 2]
US$ 24.22
US$ 24.61
US$ 26.13
US$ 20.50
US$ 27.34
US$ 28.52
US$ 23.79
US$ 28.51
